<DOC>
	<DOCNO>NCT01870674</DOCNO>
	<brief_summary>Study evaluate safety/tolerability pharmacokinetics/pharmacodynamics ( PK/PD ) YH12852 oral administration healthy subject</brief_summary>
	<brief_title>Safety/Tolerability Pharmacokinetics/Pharmacodynamics YH12852 After Oral Administration Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>healthy male/female age 19 45 body mass index ( BMI ) 18 25kg/m2 Subject congenital , chronic disease disease symptoms medical examination result Subject judge eligible principal investigator subinvestigator accord various reason include abnormal test result ( clinical laboratory test , 12lead ECG etc ) Subjects sign write informed consent voluntarily , prior procedure , use form approve local Institutional Review Board detail explanation purpose , content , characteristic drug Subject history presence clinically significant disease liver , kidney , gastrointestinal tract , nervous system , respiratory system , endocrine system , blood tumor , cardiovascular , urinary system , mental disorder Subject hypersensitive component contain YH12852 prucalopride aspirin/antibiotics like drug Medical history gastrointestinal disease acid restrain surgery , gastric/ esophagus surgery ( exclude appendectomy , hernia surgery ) Clinically significant abnormal value diagnostic check within 28 day treatment ( &gt; 1.25 fold normal upper limit level AST ALT , &gt; 1.5 fold normal upper limit level Total bilirubin , &lt; 80ml/min CockcroftGault use creatinine clearance Subject QTc interval 550 m PR interval 210 m QRS interval 120 m QT interval 500 m baseline 12lead ECG , determine Investigator Subject take usual dose prescription drug within 14 day treatment use usual dose OTC drug within 7 day treatment Subject participate another clinical trail within 2 month enrol study subject donate whole blood within 2 month component blood within 1 month treatment Medically unacceptable contraception use clinical trial Subject drink 30g/day detected alcohol positive test Subject stop smoke within 3 month treatment n't able stop smoke hospitalization Subject beverage contain caffeine hospitalization Subjects clinically significant observation consider unsuitable base medical judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>